The global biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 66.95 billion by 2030, registering a CAGR of 5.67% from 2024 to 2030, according to a new report by Grand View Research, Inc.
The growing R&D investment for innovative therapeutics by pharmaceutical and biotechnology companies, which are complex and require strict timeline follow-up, is driving outsourcing trend in the industry. Moreover, high costs associated with the new drug development in the biotechnology and pharmaceutical industries lead to customer’s preference for cost-effective outsourcing solutions. CROs have the required expertise and infrastructure that provide the benefit of cost, time, and efficiency. Moreover, emerging economies, such as Japan, India, and China are mostly preferred countries for outsourcing activities, owing to strong availability of experts, R&D infrastructure, and affordability.
In addition, regulatory framework for drug discovery and development is complex in several countries. Thus, increasing need for expertise in different areas of drug development is driving the demand for outsourcing services. Drug companies are not only outsourcing production of medicines but also clinical trials. Moreover, the outsourcing of manufacturing activities to developing countries such as China, India, and Latin America is growing due to expanding privatization of clinical trials. Additionally, the globalization of clinical trials has increased the demand for outsourcing services, particularly in emerging markets such as Latin America and MEA owing to large patient pool and lower costs
Regulatory approval procedures are becoming more stringent & time-consuming, and business players aim to receive product approvals at the first attempt to gain a higher market share. Pharmaceutical and biotechnology companies are required to have an in-house regulatory department or outsource their regulatory affairs functions due to stringent regulatory requirements in developed countries and changing regulations in developing countries. Establishing an in-house regulatory affairs department in offshore countries is not feasible, thus companies are adopting different outsourcing models depending upon size and priority of projects, thereby contributing to the growth of global biotechnology/pharmaceutical services outsourcing market.
Pharmaceutical and biotechnology companies are now focusing on their core competencies and outsourcing non-core functions to increase their productivity & operational efficiency. These companies commonly outsource R&D functions to emerging regions, such as Asia Pacific, and have now started outsourcing product design & development to CROs to reduce cost & increase focus on core functions. Small- or mid-sized companies, which do not have in-house capabilities, have to outsource their product design and development, auditing, and regulatory affairs to enter into new markets. Small or specialty companies are hiring CRO consultants to assist in regulatory affairs and legal representation functions in international markets.
The growing R&D investment for innovative therapeutics by pharmaceutical and biotechnology companies, which are complex and require strict timeline follow-up, is driving outsourcing trend in the industry. Moreover, high costs associated with the new drug development in the biotechnology and pharmaceutical industries lead to customer’s preference for cost-effective outsourcing solutions. CROs have the required expertise and infrastructure that provide the benefit of cost, time, and efficiency. Moreover, emerging economies, such as Japan, India, and China are mostly preferred countries for outsourcing activities, owing to strong availability of experts, R&D infrastructure, and affordability.
In addition, regulatory framework for drug discovery and development is complex in several countries. Thus, increasing need for expertise in different areas of drug development is driving the demand for outsourcing services. Drug companies are not only outsourcing production of medicines but also clinical trials. Moreover, the outsourcing of manufacturing activities to developing countries such as China, India, and Latin America is growing due to expanding privatization of clinical trials. Additionally, the globalization of clinical trials has increased the demand for outsourcing services, particularly in emerging markets such as Latin America and MEA owing to large patient pool and lower costs
Regulatory approval procedures are becoming more stringent & time-consuming, and business players aim to receive product approvals at the first attempt to gain a higher market share. Pharmaceutical and biotechnology companies are required to have an in-house regulatory department or outsource their regulatory affairs functions due to stringent regulatory requirements in developed countries and changing regulations in developing countries. Establishing an in-house regulatory affairs department in offshore countries is not feasible, thus companies are adopting different outsourcing models depending upon size and priority of projects, thereby contributing to the growth of global biotechnology/pharmaceutical services outsourcing market.
Pharmaceutical and biotechnology companies are now focusing on their core competencies and outsourcing non-core functions to increase their productivity & operational efficiency. These companies commonly outsource R&D functions to emerging regions, such as Asia Pacific, and have now started outsourcing product design & development to CROs to reduce cost & increase focus on core functions. Small- or mid-sized companies, which do not have in-house capabilities, have to outsource their product design and development, auditing, and regulatory affairs to enter into new markets. Small or specialty companies are hiring CRO consultants to assist in regulatory affairs and legal representation functions in international markets.
Biotechnology And Pharmaceutical Services Outsourcing Market Report Highlights
- Based on services, the consulting segment dominated the market in 2023. The high segment growth is driven by increasing changes in regulations by several regulatory authorities such as U.S. FDA and EMA creating the need for regulatory compliance for pharmaceutical & biotech companies. Pharmaceutical and biotech products may face withdrawals, recalls, repacking, or relabeling if products are not compliant with the regulatory standards, thereby preferring consulting services from third party organizations to ensure compliance with evolving regulations
- Based on end-use, the pharmaceutical companies segment held majority revenue share, accounting of over 58.44% in 2023. Growth in the segment can be attributed to factors such as increase in outsourcing of regulatory services and product design & development services by pharmaceutical companies to avoid high capital expenditure and increase profit margins
- Asia Pacific dominated the market with a share of 42.41% in 2023. The regional growth is owing to surge in R&D investments by developed countries and numerous regulatory reforms in clinical trial assessment to align with regulatory guidelines of various countries investing in the region
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Details of Primary Research
1.6. Market Formulation & Validation
1.7. Region-wise Market Calculation
1.7.1. Region-Wise Market: Base Estimates
1.7.2. Global Market: CAGR Calculation
1.7.3. Region Based Segment Share Calculation
1.8. Model Details
1.8.1. Commodity Flow Analysis (Model 1)
1.8.1.1. Approach 1: Commodity Flow Approach
1.8.2. Value Chain-based Sizing & Forecasting (Model 2)
1.8.3. QFD Model Sizing & Forecasting (Model 3)
1.8.4. Bottom-up Approach (Model 4)
1.9. Research Scope and Assumptions
1.10. List of Secondary Sources
1.11. List of Primary Sources
1.12. List of Abbreviations
1.13. Objectives
1.13.1. Objective 1
1.13.2. Objective 2
1.13.3. Objective 3
1.13.4. Objective 4
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Details of Primary Research
1.6. Market Formulation & Validation
1.7. Region-wise Market Calculation
1.7.1. Region-Wise Market: Base Estimates
1.7.2. Global Market: CAGR Calculation
1.7.3. Region Based Segment Share Calculation
1.8. Model Details
1.8.1. Commodity Flow Analysis (Model 1)
1.8.1.1. Approach 1: Commodity Flow Approach
1.8.2. Value Chain-based Sizing & Forecasting (Model 2)
1.8.3. QFD Model Sizing & Forecasting (Model 3)
1.8.4. Bottom-up Approach (Model 4)
1.9. Research Scope and Assumptions
1.10. List of Secondary Sources
1.11. List of Primary Sources
1.12. List of Abbreviations
1.13. Objectives
1.13.1. Objective 1
1.13.2. Objective 2
1.13.3. Objective 3
1.13.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Outsourcing of R&D Activities
3.2.1.2. Changing Regulatory Landscape
3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
3.2.1.4. Growing Drug Development Costs Coupled with High Clinical Development Failure Rates
3.2.1.5. Increasing Mergers and Collaborations
3.2.2. Market Restraint Analysis
3.2.2.1. Monitoring Issues and Lack of Standardization\
3.2.2.2. Loss of Control
3.2.2.3. Data Security Issues
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Clinical Trials Volume Analysis
3.6. R&D Investment Analysis
3.7. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
3.7.1. Porter’s Five Forces Analysis
3.7.2. PESTEL Analysis
3.8. COVID-19 Impact Analysis
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Outsourcing of R&D Activities
3.2.1.2. Changing Regulatory Landscape
3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
3.2.1.4. Growing Drug Development Costs Coupled with High Clinical Development Failure Rates
3.2.1.5. Increasing Mergers and Collaborations
3.2.2. Market Restraint Analysis
3.2.2.1. Monitoring Issues and Lack of Standardization\
3.2.2.2. Loss of Control
3.2.2.3. Data Security Issues
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Clinical Trials Volume Analysis
3.6. R&D Investment Analysis
3.7. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
3.7.1. Porter’s Five Forces Analysis
3.7.2. PESTEL Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
4.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
4.4. Consulting
4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.2. Regulatory Consulting
4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.3. Clinical Development Consulting
4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.4. Strategic Planning & Business Development Consulting
4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.5. Quality Management Systems Consulting
4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.6. Others
4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Regulatory Affairs
4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.2. Legal Representation
4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.3. Regulatory Writing & Publishing
4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.4. Product Registration & Clinical Trial Applications
4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.5. Regulatory Submissions
4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.6. Regulatory Operations
4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.7. Others
4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.6. Product Design & Development
4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.7. Auditing and Assessment
4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.8. Product Maintenance
4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.9. Training & Education
4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.10. Others
4.10.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
4.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
4.4. Consulting
4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.2. Regulatory Consulting
4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.3. Clinical Development Consulting
4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.4. Strategic Planning & Business Development Consulting
4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.5. Quality Management Systems Consulting
4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4.6. Others
4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Regulatory Affairs
4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.2. Legal Representation
4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.3. Regulatory Writing & Publishing
4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.4. Product Registration & Clinical Trial Applications
4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.5. Regulatory Submissions
4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.6. Regulatory Operations
4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.5.7. Others
4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.6. Product Design & Development
4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.7. Auditing and Assessment
4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.8. Product Maintenance
4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.9. Training & Education
4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.10. Others
4.10.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
5.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
5.4. Pharmaceutical Companies
5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.5. Biotech Companies
5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
5.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
5.4. Pharmaceutical Companies
5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.5. Biotech Companies
5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Estimates & Trend Analysis, by Service, by End-Use
6.1. Regional Dashboard
6.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis
6.3. North America
6.3.1. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.2. U.S.
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.3. Canada
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Europe
6.4.1. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.2. UK
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. Germany
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. France
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.5. Italy
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.6. Spain
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.7. Denmark
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.8. Sweden
6.4.8.1. Key Country Dynamics
6.4.8.2. Competitive Scenario
6.4.8.3. Regulatory Framework
6.4.8.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.9. Norway
6.4.9.1. Key Country Dynamics
6.4.9.2. Competitive Scenario
6.4.9.3. Regulatory Framework
6.4.9.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Asia-Pacific
6.5.1. Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.2. Japan
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. China
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.4. India
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.5. Australia
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.7. South Korea
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Latin America
6.6.1. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.2. Brazil
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. Mexico
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. Argentina
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7. Middle East & Africa
6.7.1. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.2. South Africa
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.3. Saudi Arabia
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.4. UAE
6.7.4.1. Key Country Dynamics
6.7.4.2. Competitive Scenario
6.7.4.3. Regulatory Framework
6.7.4.4. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.5. Kuwait
6.7.5.1. Key Country Dynamics
6.7.5.2. Competitive Scenario
6.7.5.3. Regulatory Framework
6.7.5.4. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis
6.3. North America
6.3.1. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.2. U.S.
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.3.3. Canada
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Europe
6.4.1. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.2. UK
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. Germany
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. France
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.5. Italy
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.6. Spain
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.7. Denmark
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.8. Sweden
6.4.8.1. Key Country Dynamics
6.4.8.2. Competitive Scenario
6.4.8.3. Regulatory Framework
6.4.8.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.9. Norway
6.4.9.1. Key Country Dynamics
6.4.9.2. Competitive Scenario
6.4.9.3. Regulatory Framework
6.4.9.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Asia-Pacific
6.5.1. Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.2. Japan
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. China
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.4. India
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.5. Australia
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.7. South Korea
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Latin America
6.6.1. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.2. Brazil
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. Mexico
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. Argentina
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7. Middle East & Africa
6.7.1. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.2. South Africa
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.3. Saudi Arabia
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.4. UAE
6.7.4.1. Key Country Dynamics
6.7.4.2. Competitive Scenario
6.7.4.3. Regulatory Framework
6.7.4.4. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.5. Kuwait
6.7.5.1. Key Country Dynamics
6.7.5.2. Competitive Scenario
6.7.5.3. Regulatory Framework
6.7.5.4. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Company Market Share/Assessment Analysis, 2023
7.3. Service Heat Map Analysis
7.4. Company Profiles
7.4.1. Parexel International Corporation
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Service Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. The Quantic Group
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Service Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. IQVIA
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Service Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Lachman Consultant Services, Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Service Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. GMP Pharmaceuticals Pty Ltd.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Service Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Concept Heidelberg GmbH
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Service Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. LabCorp
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Service Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Charles River Laboratories
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Service Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. ICON Plc.
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Service Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Syneos Health
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Service Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Lonza
7.4.11.1. Company Overview
7.4.11.2. Financial Performance
7.4.11.3. Service Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. Catalent Inc.
7.4.12.1. Company Overview
7.4.12.2. Financial Performance
7.4.12.3. Service Benchmarking
7.4.12.4. Strategic Initiatives
7.4.13. Samsung Biologics
7.4.13.1. Company Overview
7.4.13.2. Financial Performance
7.4.13.3. Service Benchmarking
7.4.13.4. Strategic Initiatives
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Company Market Share/Assessment Analysis, 2023
7.3. Service Heat Map Analysis
7.4. Company Profiles
7.4.1. Parexel International Corporation
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Service Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. The Quantic Group
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Service Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. IQVIA
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Service Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Lachman Consultant Services, Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Service Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. GMP Pharmaceuticals Pty Ltd.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Service Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Concept Heidelberg GmbH
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Service Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. LabCorp
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Service Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Charles River Laboratories
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Service Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. ICON Plc.
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Service Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Syneos Health
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Service Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Lonza
7.4.11.1. Company Overview
7.4.11.2. Financial Performance
7.4.11.3. Service Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. Catalent Inc.
7.4.12.1. Company Overview
7.4.12.2. Financial Performance
7.4.12.3. Service Benchmarking
7.4.12.4. Strategic Initiatives
7.4.13. Samsung Biologics
7.4.13.1. Company Overview
7.4.13.2. Financial Performance
7.4.13.3. Service Benchmarking
7.4.13.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 4 Global Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 5 Global Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 6 Global Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 7 Global Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 8 Global Biotechnology and Pharmaceutical Services Outsourcing by Region, 2018-2030 (USD Million)
Table 9 North America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 10 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 11 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 12 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 13 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 14 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 15 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 16 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 17 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 18 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 19 U.S. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 20 Canada Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 21 Canada Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 22 Canada Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 23 Canada Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 24 Canada Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 25 Europe Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 26 Europe Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 27 Europe Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 28 Europe Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 29 Europe Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 30 Europe Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 31 Germany Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 32 Germany Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 33 Germany Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 34 Germany Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 35 Germany Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 36 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 37 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 38 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 39 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 40 U.K. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 41 France Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 42 France Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 43 France Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 44 France Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 45 France Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 46 Italy Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 47 Italy Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 48 Italy Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 49 Italy Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 50 Italy Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 51 Spain Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 52 Spain Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 53 Spain Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 54 Spain Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 55 Spain Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 56 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 57 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 58 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 59 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 60 Denmark Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 61 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 62 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 63 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 64 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 65 Sweden Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 66 Norway Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 67 Norway Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 68 Norway Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 69 Norway Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 70 Norway Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 71 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 72 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 73 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 74 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 75 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 76 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 77 China Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 78 China Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 79 China Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 80 China Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 81 China Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 82 Japan Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 83 Japan Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 84 Japan Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 85 Japan Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 86 Japan Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 87 India Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 88 India Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 89 India Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 90 India Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 91 India Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 92 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 93 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 94 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 95 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 96 South Korea Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 97 Australia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 98 Australia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 99 Australia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 100 Australia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 101 Australia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 102 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 103 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 104 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 105 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 106 Thailand Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 107 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 108 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 109 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 110 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 111 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 112 Latin America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 113 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 114 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 115 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 116 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 117 Brazil Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 118 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 119 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 120 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 121 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 122 Mexico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 123 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 124 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 125 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 126 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 127 Argentina Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 128 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 129 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 130 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 131 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 132 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 133 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 134 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 135 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 136 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 137 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 138 South Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 139 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 140 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 141 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 142 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 143 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 144 UAE Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 145 UAE Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 146 UAE Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 147 UAE Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 148 UAE Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 149 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 150 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 151 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 152 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 153 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 2 List of Abbreviations
Table 3 Global Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 4 Global Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 5 Global Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 6 Global Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 7 Global Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 8 Global Biotechnology and Pharmaceutical Services Outsourcing by Region, 2018-2030 (USD Million)
Table 9 North America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 10 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 11 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 12 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 13 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 14 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 15 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 16 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 17 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 18 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 19 U.S. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 20 Canada Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 21 Canada Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 22 Canada Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 23 Canada Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 24 Canada Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 25 Europe Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 26 Europe Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 27 Europe Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 28 Europe Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 29 Europe Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 30 Europe Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 31 Germany Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 32 Germany Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 33 Germany Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 34 Germany Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 35 Germany Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 36 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 37 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 38 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 39 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 40 U.K. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 41 France Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 42 France Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 43 France Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 44 France Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 45 France Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 46 Italy Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 47 Italy Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 48 Italy Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 49 Italy Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 50 Italy Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 51 Spain Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 52 Spain Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 53 Spain Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 54 Spain Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 55 Spain Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 56 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 57 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 58 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 59 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 60 Denmark Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 61 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 62 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 63 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 64 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 65 Sweden Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 66 Norway Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 67 Norway Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 68 Norway Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 69 Norway Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 70 Norway Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 71 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 72 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 73 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 74 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 75 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 76 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 77 China Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 78 China Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 79 China Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 80 China Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 81 China Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 82 Japan Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 83 Japan Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 84 Japan Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 85 Japan Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 86 Japan Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 87 India Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 88 India Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 89 India Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 90 India Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 91 India Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 92 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 93 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 94 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 95 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 96 South Korea Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 97 Australia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 98 Australia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 99 Australia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 100 Australia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 101 Australia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 102 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 103 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 104 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 105 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 106 Thailand Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 107 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 108 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 109 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 110 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 111 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 112 Latin America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 113 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 114 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 115 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 116 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 117 Brazil Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 118 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 119 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 120 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 121 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 122 Mexico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 123 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 124 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 125 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 126 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 127 Argentina Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 128 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018-2030 (USD Million)
Table 129 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 130 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 131 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 132 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 133 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 134 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 135 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 136 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 137 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 138 South Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 139 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 140 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 141 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 142 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 143 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 144 UAE Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 145 UAE Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 146 UAE Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 147 UAE Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 148 UAE Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
Table 149 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018-2030 (USD Million)
Table 150 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018-2030 (USD Million)
Table 151 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018-2030 (USD Million)
Table 152 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018-2030 (USD Million)
Table 153 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018-2030 (USD Million)
List of Figures
Figure 1 Information Procurement
Figure 2 Primary Research Pattern
Figure 3 Market Research Approaches
Figure 4 Value Chain-based Sizing & Forecasting
Figure 5 Market Formulation & Validation
Figure 6 Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
Figure 7 Market Driver Relevance Analysis (Current & Future Impact)
Figure 8 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 9 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
Figure 10 Porter’s Five Forces Analysis
Figure 11 Regional Marketplace: Key Takeaways
Figure 12 Global Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018-2030 (USD Million)
Figure 13 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018-2030 (USD Million)
Figure 14 Global Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018-2030 (USD Million)
Figure 15 Global Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018-2030 (USD Million)
Figure 16 Global Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018-2030 (USD Million)
Figure 17 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018-2030 (USD Million)
Figure 18 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018-2030 (USD Million)
Figure 19 Global Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018-2030 (USD Million)
Figure 20 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018-2030 (USD Million)
Figure 21 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018-2030 (USD Million)
Figure 22 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018-2030 (USD Million)
Figure 23 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018-2030 (USD Million)
Figure 24 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018-2030 (USD Million)
Figure 25 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018-2030 (USD Million)
Figure 26 Global Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018-2030 (USD Million)
Figure 27 Global Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018-2030 (USD Million)
Figure 28 Global Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018-2030 (USD Million)
Figure 29 Global Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation , 2018-2030 (USD Million)
Figure 30 Global Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer , 2018-2030 (USD Million)
Figure 31 Global Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018-2030 (USD Million)
Figure 32 Global Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018-2030 (USD Million)
Figure 33 Global Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018-2030 (USD Million)
Figure 34 Regional Outlook, 2023 & 2030
Figure 35 North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 36 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 37 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 38 Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 39 Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 40 UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 41 France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 42 Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 43 Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 44 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 45 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 46 Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 47 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 48 Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 49 China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 50 India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 51 Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 52 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 53 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 54 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 55 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 56 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 57 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 58 Middle East and Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 59 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 60 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 61 UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 62 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 2 Primary Research Pattern
Figure 3 Market Research Approaches
Figure 4 Value Chain-based Sizing & Forecasting
Figure 5 Market Formulation & Validation
Figure 6 Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
Figure 7 Market Driver Relevance Analysis (Current & Future Impact)
Figure 8 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 9 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
Figure 10 Porter’s Five Forces Analysis
Figure 11 Regional Marketplace: Key Takeaways
Figure 12 Global Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018-2030 (USD Million)
Figure 13 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018-2030 (USD Million)
Figure 14 Global Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018-2030 (USD Million)
Figure 15 Global Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018-2030 (USD Million)
Figure 16 Global Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018-2030 (USD Million)
Figure 17 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018-2030 (USD Million)
Figure 18 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018-2030 (USD Million)
Figure 19 Global Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018-2030 (USD Million)
Figure 20 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018-2030 (USD Million)
Figure 21 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018-2030 (USD Million)
Figure 22 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018-2030 (USD Million)
Figure 23 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018-2030 (USD Million)
Figure 24 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018-2030 (USD Million)
Figure 25 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018-2030 (USD Million)
Figure 26 Global Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018-2030 (USD Million)
Figure 27 Global Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018-2030 (USD Million)
Figure 28 Global Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018-2030 (USD Million)
Figure 29 Global Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation , 2018-2030 (USD Million)
Figure 30 Global Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer , 2018-2030 (USD Million)
Figure 31 Global Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018-2030 (USD Million)
Figure 32 Global Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018-2030 (USD Million)
Figure 33 Global Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018-2030 (USD Million)
Figure 34 Regional Outlook, 2023 & 2030
Figure 35 North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 36 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 37 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 38 Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 39 Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 40 UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 41 France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 42 Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 43 Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 44 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 45 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 46 Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 47 Asia-Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 48 Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 49 China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 50 India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 51 Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 52 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 53 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 54 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 55 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 56 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 57 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 58 Middle East and Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 59 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 60 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 61 UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 62 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018-2030 (USD Million)
Companies Mentioned
- Parexel International Corporation
- The Quantic Group
- IQVIA
- Lachman Consultant Services, Inc.
- GMP Pharmaceuticals Pty Ltd.
- Concept Heidelberg GmbH
- LabCorp
- Charles River Laboratories
- ICON plc.
- Syneos Health
- Lonza
- Catalent Inc.
- Samsung Biologics
Methodology
LOADING...
